GLP-1 Therapies in Cardiology Clinical Practice
GLP-1 therapies are shown to reduce cardiovascular events, possibly by reducing visceral adipose tissue. This suggests a shift in cardiology practice towards targeting upstream metabolic diseases.
GLP-1 therapies are shown to reduce cardiovascular events, possibly by reducing visceral adipose tissue. This suggests a shift in cardiology practice towards targeting upstream metabolic diseases.